Physician profile
Stanislaw Burzynski
NPI 1093836819
$1,116.97
in general payments reported to CMS, 2019-2025
14 companies · $19.42 in 2025
The $19.42 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $159 · 2021: $41.19 · 2022: $194 · 2023: $64.99 · 2024: $182 · 2025: $19.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.94 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $182.97 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $171.90 | 2019-2022 | |
| Tempus Ai, INC | $138.89 | 2024-2025 | Xt Cdx, Tempus Pixel |
| Janssen Biotech, INC. | $109.17 | 2022-2023 | Erleada |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Verastem, INC. | $67.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.09 | 2019-2020 | |
| Sobi, INC | $62.05 | 2024 | |
| Foundation Medicine, INC. | $59.99 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $46.74 | 2019-2020 | |
| Amgen INC. | $40.91 | 2019-2020 | |
| Kyowa Kirin, INC. | $29.77 | 2020 | |
| Tesaro, INC. | $22.69 | 2019 | |
| Taiho Oncology, INC. | $22.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislaw Burzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.